Probenecid inhibits the glucuronidation of indomethacin andO-desmethylindomethacin in humans

[1]  T. Vree,et al.  Probenecid inhibits the renal clearance and renal glucuronidation of nalidixic acid , 1993, Pharmacy World and Science.

[2]  T. Vree,et al.  Direct gradient reversed-phase HPLC analysis and preliminary pharmacokinetics of nalidixic acid, 7-hydroxymethylnalidixic acid, 7-carboxynalidixic acid, and their corresponding glucuronide conjugates in humans , 1993, Pharmacy World and Science.

[3]  T. Vree,et al.  Capacity-limited renal glucuronidation of probenecid by humans , 1992, Pharmaceutisch Weekblad.

[4]  D. Meijer,et al.  Clearance of indometacin occurs predominantly by renal glucuronidation , 1992, Pharmaceutisch Weekblad.

[5]  T. Vree,et al.  Direct measurement of probenecid and its glucuronide conjugate by means of high pressure liquid chromatography in plasma and urine of humans , 1992, Pharmaceutisch Weekblad.

[6]  T. Vree,et al.  Pharmacokinetics of naproxen, its metabolite O‐desmethylnaproxen, and their acyl glucuronides in humans , 1993, Biopharmaceutics & drug disposition.

[7]  T. Vree,et al.  Determination of indomethacin, its metabolites and their glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatographic analysis. Preliminary pharmacokinetics and effect of probenecid. , 1993, Journal of chromatography.

[8]  T. Vree,et al.  The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effect of cimetidine. , 1993, British journal of clinical pharmacology.

[9]  T. Vree,et al.  Contribution of the Human Kidney to the Metabolic Clearance of Drugs , 1992, The Annals of pharmacotherapy.

[10]  T. Vree,et al.  Direct-gradient high-performance liquid chromatographic analysis and preliminary pharmacokinetics of flumequine and flumequine acyl glucuronide in humans: effect of probenecid. , 1992, Journal of chromatography.

[11]  T. Vree,et al.  Determination of naproxen and its metabolite O-desmethylnaproxen with their acyl glucuronides in human plasma and urine by means of direct gradient high-performance liquid chromatography. , 1992, Journal of chromatography.

[12]  J. Proost,et al.  MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring. , 1992, Computers in biology and medicine.

[13]  F. Russel,et al.  Naproxen and indomethacin: disposition and effects in the isolated perfused rat kidney. , 1990, Toxicology letters.

[14]  E M Faed,et al.  Properties of acyl glucuronides: implications for studies of the pharmacokinetics and metabolism of acidic drugs. , 1984, Drug metabolism reviews.

[15]  L. Helleberg.  Clinical Pharmacokinetics of Indomethacin , 1981, Clinical pharmacokinetics.

[16]  N. Holford,et al.  Negligible excretion of unchanged ketoprofen, naproxen, and probenecid in urine. , 1980, Journal of pharmaceutical sciences.

[17]  F. Mcmahon,et al.  The metabolism of indomethacin in man. , 1972, The Journal of pharmacology and experimental therapeutics.

[18]  L. A. Healey,et al.  The renal excretion of indomethacin and its inhibition by probenecid , 1968, Clinical pharmacology and therapeutics.

[19]  A. G. Zacchei,et al.  STUDIES ON THE ABSORPTION, DISTRIBUTION AND EXCRETION OF INDOMETHACIN IN VARIOUS SPECIES , 1966 .

[20]  F. Kuehl,et al.  THE METABOLITES OF INDOMETHACIN, A NEW ANTI-INFLAMMATORY DRUG. , 1964, The Journal of pharmacology and experimental therapeutics.